NOT FOR DISTRIBUTION
Header cover image

Carl Zeiss Meditec

Market Cap

€12.5b

Last Updated

2021/05/15 19:45 UTC

Data Sources

Company Financials +

Executive Summary

Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, France, Spain, India, the United Kingdom, Turkey, North Africa, and internationally. More Details

Rewards

Earnings are forecast to grow 13.71% per year

Risk Analysis

No risks detected for AFX from our risk checks.


Snowflake Analysis

Flawless balance sheet with acceptable track record.


Similar Companies

Share Price & News

How has Carl Zeiss Meditec's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AFX is less volatile than 75% of German stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: AFX's weekly volatility (3%) has been stable over the past year.


Market Performance


7 Day Return

-3.6%

AFX

-4.6%

DE Medical Equipment

-0.8%

DE Market


1 Year Return

66.9%

AFX

24.3%

DE Medical Equipment

39.4%

DE Market

Return vs Industry: AFX exceeded the German Medical Equipment industry which returned 24.2% over the past year.

Return vs Market: AFX exceeded the German Market which returned 39.5% over the past year.


Shareholder returns

AFXIndustryMarket
7 Day-3.6%-4.6%-0.8%
30 Day-3.9%-3.6%-1.4%
90 Day4.5%-6.7%5.2%
1 Year68.1%66.9%25.8%24.3%44.4%39.4%
3 Year144.8%141.3%80.1%72.5%20.1%10.1%
5 Year321.8%307.8%321.6%305.4%55.3%33.7%

Long-Term Price Volatility Vs. Market

How volatile is Carl Zeiss Meditec's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Carl Zeiss Meditec undervalued compared to its fair value and its price relative to the market?

78.55x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: AFX (€139.85) is trading above our estimate of fair value (€109.66)

Significantly Below Fair Value: AFX is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: AFX is poor value based on its PE Ratio (78.5x) compared to the German Medical Equipment industry average (35.1x).

PE vs Market: AFX is poor value based on its PE Ratio (78.5x) compared to the German market (25.9x).


Price to Earnings Growth Ratio

PEG Ratio: AFX is poor value based on its PEG Ratio (5.7x)


Price to Book Ratio

PB vs Industry: AFX is overvalued based on its PB Ratio (8.1x) compared to the DE Medical Equipment industry average (7.6x).


Future Growth

How is Carl Zeiss Meditec forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

13.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AFX's forecast earnings growth (13.7% per year) is above the savings rate (0.01%).

Earnings vs Market: AFX's earnings (13.7% per year) are forecast to grow slower than the German market (16.2% per year).

High Growth Earnings: AFX's earnings are forecast to grow, but not significantly.

Revenue vs Market: AFX's revenue (7.2% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: AFX's revenue (7.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AFX's Return on Equity is forecast to be low in 3 years time (15.1%).


Past Performance

How has Carl Zeiss Meditec performed over the past 5 years?

9.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AFX has high quality earnings.

Growing Profit Margin: AFX's current net profit margins (11.5%) are higher than last year (11%).


Past Earnings Growth Analysis

Earnings Trend: AFX's earnings have grown by 9% per year over the past 5 years.

Accelerating Growth: AFX's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: AFX had negative earnings growth (-3.9%) over the past year, making it difficult to compare to the Medical Equipment industry average (58.9%).


Return on Equity

High ROE: AFX's Return on Equity (10.2%) is considered low.


Financial Health

How is Carl Zeiss Meditec's financial position?


Financial Position Analysis

Short Term Liabilities: AFX's short term assets (€1.5B) exceed its short term liabilities (€347.9M).

Long Term Liabilities: AFX's short term assets (€1.5B) exceed its long term liabilities (€306.6M).


Debt to Equity History and Analysis

Debt Level: AFX is debt free.

Reducing Debt: AFX has no debt compared to 5 years ago when its debt to equity ratio was 0.1%.

Debt Coverage: AFX has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: AFX has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Carl Zeiss Meditec current dividend yield, its reliability and sustainability?

0.36%

Current Dividend Yield


Upcoming Dividend Payment

TodayMay 16 2021Ex Dividend DateMay 28 2021Dividend Pay DateJun 01 20214 days from Ex DividendBuy in the next 12 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: AFX's dividend (0.36%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.06%).

High Dividend: AFX's dividend (0.36%) is low compared to the top 25% of dividend payers in the German market (3.26%).


Stability and Growth of Payments

Stable Dividend: AFX is not paying a notable dividend for the German market, therefore no need to check if payments are stable.

Growing Dividend: AFX is not paying a notable dividend for the German market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: AFX is not paying a notable dividend for the German market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AFX's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure


CEO

Ludwin Monz (57 yo)

11.17yrs

Tenure

€1,908,900

Compensation

Dr. Ludwin Monz, Ph.D., M.B.A. has been the Chairman of Management Board at Carl Zeiss Meditec AG since October 8, 2007. Dr. Monz has been the Chief Executive Officer and President of Carl Zeiss Meditec AG...


CEO Compensation Analysis

Compensation vs Market: Ludwin's total compensation ($USD2.32M) is below average for companies of similar size in the German market ($USD5.37M).

Compensation vs Earnings: Ludwin's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: AFX's management team is considered experienced (2.6 years average tenure).


Board Members

Experienced Board: AFX's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Carl Zeiss Meditec AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Carl Zeiss Meditec AG
  • Ticker: AFX
  • Exchange: XTRA
  • Founded: 2002
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €12.508b
  • Shares outstanding: 89.44m
  • Website: https://www.zeiss.de/meditec-ag/home.html

Number of Employees


Location

  • Carl Zeiss Meditec AG
  • Goschwitzer Strasse 51-52
  • Jena
  • Thuringia
  • 7745
  • Germany

Listings


Biography

Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, France, Spain, India, the United Kingdom, Turkey, North Africa, and internationally. It operates in two ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/15 19:45
End of Day Share Price2021/05/14 00:00
Earnings2021/03/31
Annual Earnings2020/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.